Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03398200 · ClinicalTrials.gov registry record · Phase 2
Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma
A Phase 2 study of Myeloma, sponsored by Omar Aljitawi.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 3
- Study locations
NCT03398200: Completed Phase 2 study of Myeloma, sponsored by Omar Aljitawi.
NCT03398200 is a Phase 2 study of Myeloma that has completed, run by Omar Aljitawi. The registered enrollment target is 99 participants, roughly in line with the 96-participant average among 29 other Myeloma trials with a reported enrollment target. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03398200, a Phase 2 study of Myeloma, has completed, sponsored by Omar Aljitawi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 3
- Study locations
Study Summary
Patients with Multiple Myeloma who are considered for high-dose therapy and autologous transplantation at the bone marrow transplant clinic at the Wilmot Cancer Institute (WCI) will be be approached to participate in this trial. Eligible patients who choose to participate will be randomized so that half receive one hyperbaric oxygen therapy session prior to hematopoetic stem cell infusion and half will not. All subjects will have their blood counts monitored closely and time to count recovery will be compared between the two groups.
Primary Outcome
Time from transplant to neutrophil recovery was measured as the first day of absolute neutrophil count \>=0.5 thou/ul after nadir.
Conditions Studied
Interventions
- BIOLOGICAL Hyperbaric Oxygen Therapy
- OTHER No Hyperbaric Oxygen Therapy
Study Locations (3)
Kansas
- The University of Kansas Cancer Center - Fairway
Kentucky
- University of Kentucky Markey Cancer Center - Lexington
New York
- Wilmot Cancer Institute, University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2018-05-10 |
| Est. Completion | 2023-03-28 |
| Phase | Phase 2 |
What the finished NCT03398200 record still lists
NCT03398200 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, roughly in line with the 96-participant average among 29 other Myeloma trials with a reported enrollment target.
The record links to 1 condition, with Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Hyperbaric Oxygen Therapy is the first listed.
NCT03398200 reports a single indexed study location in Kansas, Kentucky, New York.
Frequently Asked Questions
What is clinical trial NCT03398200 about?
NCT03398200 is a clinical study titled "Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma". Patients with Multiple Myeloma who are considered for high-dose therapy and autologous transplantation at the bone marrow transplant clinic at the Wilmot Cancer Institute (WCI) will be be approached to participate in this trial. Eligible patients who choose to participate will be randomized so that ...
What is the current status of trial NCT03398200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2018-05-10. Estimated completion is 2023-03-28.
What conditions does trial NCT03398200 study?
This clinical trial studies the following conditions: Myeloma.
What interventions are being tested in trial NCT03398200?
The interventions under investigation include: Hyperbaric Oxygen Therapy (BIOLOGICAL), No Hyperbaric Oxygen Therapy (OTHER).
Who is sponsoring clinical trial NCT03398200?
This trial is sponsored by Omar Aljitawi, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03398200 being conducted?
This trial has 3 study locations across Kansas, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03398200's enrollment target sits among peer trials
99 7th of 29 higher than 23 of 29 other Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
RECRUITING · Phase 2
-
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
COMPLETED · Phase 2
-
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI